Related Experiment Video
Updated: May 6, 2026
07:53
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
11.5K
Increased Anti-Psoriatic Effect of Anti-Inflammatory Dendrimers Using Fluid Catanionic Vesicle-Based Topical
Ranime Jebbawi1,2, Abdelouahd Oukhrib1,3, Emily Clement2,4
1Laboratoire Softmat, Université de Toulouse, CNRS UMR 5623, Toulouse, France.
Advanced Healthcare Materials
|December 4, 2025
Summary
New dendrimer formulations show promise for treating psoriasis. Encapsulated in fluid vesicles, these compounds effectively penetrate the skin, reducing inflammation and disease severity in mice, offering a novel topical therapy.
Area of Science:
- Dermatology and Nanotechnology
- Immunomodulation and Drug Delivery
Background:
- Psoriasis is a chronic inflammatory skin condition necessitating advanced anti-inflammatory treatments.
- Current treatments face limitations, driving the need for improved topical therapies with enhanced skin penetration.
- Dendrimers, like IMD-006, show immunomodulatory potential but require optimized delivery systems.
Purpose of the Study:
- To develop and evaluate fluid vesicle formulations for enhanced delivery of dendrimers for psoriasis treatment.
- To synthesize more hydrolytically stable dendrimer analogues (IMD-036, IMD-046) and fluorescent derivatives.
- To assess the anti-psoriatic efficacy of these novel formulations in a murine model.
Main Methods:
- Synthesis of stable dendrimer analogues (IMD-036, IMD-046) and fluorescent derivatives.
- Encapsulation of dendrimers within TriCat catanionic vesicles for improved cellular uptake and skin penetration.
- Formulation of a xanthan-based hydrogel for topical application of dendrimer-loaded vesicles.
- Evaluation of anti-psoriatic efficacy in a mouse model, assessing clinical and histopathological outcomes.
Main Results:
- Encapsulation in TriCat vesicles significantly enhanced dendrimer cellular uptake and skin penetration, facilitating deeper tissue diffusion.
- Topical application of TriCat/IMD-006 and TriCat/IMD-036 formulations in a psoriatic mouse model markedly reduced disease severity.
- The observed therapeutic effects were comparable to conventional corticosteroid treatments, with no systemic exposure.
Conclusions:
- Fluid vesicle formulations, particularly TriCat vesicles, significantly improve dendrimer delivery for topical psoriasis treatment.
- Developed dendrimer formulations demonstrate potent anti-psoriatic efficacy in a murine model, comparable to corticosteroids.
- These findings support the potential of dendrimer-based nanomedicines as innovative topical therapies for psoriasis.
